Item 8.01   Other Events
On July 15, 2021, Ocugen, Inc. (the "Company") issued a press release announcing
that it had initiated a rolling submission to Health Canada for COVAXIN™, the
Company's candidate vaccine against COVID-19, which it is co-developing with
Bharat Biotech International Limited for the U.S. and Canadian markets. A copy
of this press release is filed herewith as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
Additionally, attached as Exhibit 99.2 and incorporated herein by reference is a
presentation that the Company will post on its website on July 15, 2021 and may
use from time to time in presentations or discussions with investors, analysts,
and other parties.
Item 9.01   Financial Statements and Exhibits
The following exhibits are being filed herewith:
(d) Exhibits
Exhibit No.                Document
99.1                         Press release of Ocugen, Inc. dated July 15, 2021
99.2                         Ocugen, Inc. Presentation
104                        Cover Page Interactive Data File (embedded

within the Inline XBRL document)




                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses